TOKYO, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Sony Corporation (Sony), Mitsubishi Corporation, ADEKA CORPORATION , CHIMEI Corporation, ENEOS Corporation, Formosa Chemicals & Fibre Corporation, Hanwha Impact Corporation, Idemitsu Kosan Co., Ltd., Mitsui Chemicals, Inc., Neste Corporation, Qingdao Haier New Material Development Co., Ltd., SK Geo Centric Co., Ltd., Toray Industries, Inc., and Toray Advanced Materials Korea Inc. have jointly established the world’s first global supply chain consisting of fourteen companies across five countries and regions for the production of renewable plastics*2 that can be used in Sony’s high-performance audio-visual products. The various plastic materials manufactured through this supply chain are slated for use in Sony’s products that will be launched worldwide.＜Overview of the Entire Supply Chain＞(1) Production of renewable naphtha — Neste Corporation / (2) Production of renewable styrene monomer — Idemitsu Kosan Co., Ltd. / (3) Production of renewable polystyrene resin — Formosa Chemicals & Fibre Corporation / (4) Production of renewable para-xylene — SK Geo Centric Co., Ltd. / (5) Production of renewable para-xylene — ENEOS Corporation / (6) Production of renewable terephthalic acid — Hanwha Impact Corporation / (7) Production of renewable PET resin — Toray Advanced Materials Korea Inc. / (8) Production of renewable bisphenol-A — Mitsui Chemicals, Inc. / (9) Production of renewable polycarbonate (PC) resin — CHIMEI Corporation / (10) Production of renewable flame retardants — ADEKA CORPORATION / (11) Production of renewable PC/ABS resin — Qingdao Haier New Material Development Co., Ltd./ (12) Molding manufacturers / (13) Design and manufacturing of finished products — Sony CorporationHigh-performance products such as audio-visual equipment involve a wide variety of plastics, resulting in a complex supply chain that makes it difficult to visualize and manage the entire flow from raw materials. Additionally, plastic components that require high performance in terms of flame resistance and optical properties cannot be fully replaced with plastics produced through material recycling*3, hindering the further reduction of virgin fossil-based plastics in such products.To address these challenges, the fourteen companies collaborated to visualize the existing supply chain for Sony’s products, and created a new supply chain that enables the production of multiple types of renewable plastics from biomass resources with a mass balance approach*4. This allows Sony to proactively source raw materials for its products with the quality and properties equivalent to virgin fossil-based plastics. Defining the supply chain helps the companies track and document GHG (Greenhouse Gas) emissions data over the supply chain in a verifiable way, allowing participating companies to leverage the data to advance efforts to reduce their carbon footprint going forward.This initiative involving wide-ranging partners is part of the ‘Creating NEW from reNEWable materials' project, jointly launched by Sony, which aims to achieve zero usage of virgin fossil-based plastics through the introduction of renewable plastics, and Mitsubishi Corporation.Sony, Mitsubishi Corporation, and the supply chain partners will continue to actively promote the introduction of renewable plastics for high-performance products such as audio-visual products.About ProjectProject Introduction Video：https://youtu.be/3ba3t356sHI[About Sony Corporation]Sony Corporation is a wholly-owned subsidiary of Sony Group Corporation, responsible for the Entertainment, Technology & Services (ET&S) business. With the mission to "create the future of entertainment through the power of technology together with creators", we aim to continue to deliver Kando* to people around the world. Sony is actively promoting initiatives to reduce environmental impact as part of the Sony Group’s "Road to Zero" environmental plan, which aims for zero environmental impact by 2050. In this project, Sony will oversee the entire supply chain and promote the utilization of renewable plastics in our products. https://www.sony.co.jp/en/[About Mitsubishi Corporation]Mitsubishi Corporation (MC) is an integrated trading and investment company that develops and operates businesses across multiple industries together with its global network. MC has eight Business Groups that operate across virtually every industry: Environmental Energy, Materials Solution, Mineral Resources, Urban Development & Infrastructure, Mobility, Food Industry, Smart-Life Creation, and Power Solution. Through these eight Business Groups, MC’s activities have expanded far beyond its traditional trading operations to include project development, production, and manufacturing operations, working in collaboration with our trusted partners around the world. In this project, MC plays a comprehensive role in overseeing the supply chain, including credit delivery management, and promoting the introduction of renewable plastics into Sony products. https://www.mitsubishicorp.com/jp/en/[About ADEKA CORPORATION]ADEKA CORPORATION is a manufacturer of valuable materials with over 100 years of history. ADEKA aims to realize a sustainable society by globally expanding valuable materials that enrich people's lives, such as polymer additives that enhance plastic functionality, advanced semiconductor materials, environmental materials, food products, and agrochemicals. In this project, we manufacture flame retardants with biomass characteristics assigned using a mass balance approach. https://www.adeka.co.jp/en/[About CHIMEI Corporation]CHIMEI is a leading high-performance materials company that designs and manufactures advanced polymer materials, synthetic rubbers, and specialty chemicals, delivering innovative and sustainable solutions for industries worldwide. With a commitment to circularity, environmental responsibility, and close client collaboration, CHIMEI supports and partners with global companies to elevate product performance while jointly minimizing environmental impact. In this project, CHIMEI produces polycarbonate resin (PC) with assigned biomass characteristics using a mass balance approach. https://www.chimeicorp.com/en-US[About ENEOS Corporation]At ENEOS Corporation, our network has grown to about 12,000 ENEOS branded service stations across Japan. ENEOS is expanding business to accommodate energy transitions into sources like hydrogen and Synthetic Fuels in addition to petroleum and petrochemical products produced and manufactured at refineries and factories at various locations in Japan. The ENEOS Group aims to achieve both a stable supply of energy and materials and the realization of a carbon-neutral society, based on its commitment of “Supporting ‘today’s normal,’ taking the lead for ‘tomorrow’s normal.’” In this project, ENEOS manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.hd.eneos.co.jp/english/[About Formosa Chemicals & Fibre Corporation (FCFC)]FCFC is a comprehensive chemical company that manufactures petrochemical products, synthetic fibers, and plastics. FCFC implements a circular economy to achieve both environmental protection and industrial development, working on the development of green chemicals and the expansion of reusable materials. In this project, FCFC manufactures polystyrene (PS) with assigned biomass characteristics using a mass balance approach. https://www.fcfc.com.tw/[About Hanwha Impact Corporation]Hanwha Impact is a leading petrochemical and investment company, engaged in chemical products and next-generation energy solutions. Hanwha Impact aims to achieve a sustainable society through developing eco-friendly energy solutions and fostering future innovative technologies. In this project, Hanwha Impact produces high-purity terephthalic acid (PTA) with assigned biomass characteristics using a mass balance approach. https://www.hanwhaimpact.com/[About Idemitsu Kosan Co., Ltd.]The Idemitsu Group is engaged in the development, manufacture, and sales of a wide variety areas of Petroleum, Basic Chemicals, High-Performance Materials, Power/Renewable Energy, and in a variety of fields. Idemitsu Kosan is taking on the challenge of an energy transition to help realize a carbon-neutral and circular society by 2050. In the Basic Chemicals business, we are promoting the use of biomass feedstocks and advancing chemical recycling initiatives. In this project, Idemitsu Kosan produces styrene monomer (SM) using a mass balance approach. https://www.idemitsu.com/en/index.html[About Mitsui Chemicals, Inc.]Mitsui Chemicals is a chemical manufacturer that provides solutions for achieving a sustainable society, offering a wide range of products and services from basic chemicals to high-performance materials. Aiming for carbon neutrality by 2050, the company is working to reduce GHG emissions (Scope 1 and 2) and to maximize its contribution to GHG reductions throughout the entire product life cycle. In this project, Mitsui Chemicals produce biomass-derived bisphenol A (BPA) using the mass balance approach. https://jp.mitsuichemicals.com/en/index.htm[About Neste Corporation]Neste (NESTE, Nasdaq Helsinki) creates solutions for mitigating climate change and accelerating a shift to a circular economy. The company is the world’s leading producer of sustainable aviation fuel (SAF), renewable diesel, and renewable and circular solutions for the chemical and plastics industries. In this project, NESTE supplies renewable naphtha made from waste cooking oil and other renewable raw materials. https://www.neste.com/[About Qingdao Haier New Material Development Co., Ltd.]Haier is a global home appliance manufacturer originating, offering a wide range of products including refrigerators and washing machines. Haier New Materials, a subsidiary of the Haier Group, reduces carbon emissions and promotes the construction of a sustainable society by recycling regenerated plastic materials from disassembled home appliances. In this project, Haier produces recycled PC/ABS blended with a flame retardant with assigned biomass characteristics. https://www.haierdawn-plastics.com/[About SK Geo Centric Co., Ltd.]SKGC is a leading chemical company, offering petrochemical products such as olefins, aromatics and polymers. SKGC is upgrading our portfolio to provide more sustainable products in consumer’s daily lives. In this project, SKGC manufactures paraxylene (PX) with assigned biomass characteristics using a mass balance approach. https://www.skgeocentric.com/[About Toray Industries, Inc.]Toray Industries, Inc., is a global leader in advanced materials innovation, comprising more than 300 affiliated companies and approximately 48,000 employees worldwide. Since 1926, Toray Industries have continuously expanded our business portfolio—from Fibers & Textiles, to Resins & Chemicals, Films, Electronics & Information Materials, Carbon Fiber Composite Materials, Pharmaceuticals & Medical Products, as well as Water Treatment & Environment. April 2026 marks the 100th anniversary of Toray’s founding. In line with our Corporate Philosophy, “Contributing to society through the creation of new value with innovative ideas, technologies and products,” we will commit to delivering fundamental solutions to global-scale challenges. https://www.toray.com/ [About Toray Advanced Materials Korea Inc.]TAK is a comprehensive chemical manufacturer, offering various products from daily life to high-end industries. With consistent investing and innovation, TAK provides material solutions for climate crisis. In this project, TAK manufactures PET resin and film with assigned biomass characteristics using a mass balance approach. https://www.torayamk.com *1 In the manufacturing of audio-visual products, this initiative is regarded as a “world’s first” in that it visualizes the entire supply chain from raw materials to finished products and converts raw materials to biomass-based materials at mass-production scale.(Based on research conducted by Mitsubishi Corporation. At the time of announcement in Feb. 2026)*2 Plastics made from renewable biomass resources instead of fossil resources.*3 A method of reusing plastic materials by returning used plastics to their original form through physical processes such as crushing, cleaning, and melting, rather than discarding them.*4 This is a method of allocating the characteristics of specific raw materials, such as biomass resources, to a portion of the product based on the input amount of those materials when they are mixed with non-specific raw materials during the distribution and processing stages from raw materials to products.* "Sony", "SONY" logo and any other product names, service names or logo marks used in this press release are registered trademarks or trademarks of Sony Group Corporation or its affiliates. Other product names, service names, company names or logo marks are trademarked and copyrighted properties of their respective owners and/or licensors.* Visual content in this release may be removed without prior notice due to licensing or copyright reasons.* Kando is a Japanese word that roughly translates to the sense of awe and emotion you feel when experiencing something beautiful and amazing for the first time.MaterialityBased on the Three Corporate Principles, which serve as MC’s core philosophy, MC has continued to grow together with society by contributing to the sustainable development of society through its business activities while pursuing value creation. While continuously creating Shared Value guided by the Materiality, a set of crucial societal issues, MC will continue to strengthen its efforts towards sustainable corporate growth. Guided by this Materiality, MC will continue to strengthen its efforts towards sustainable corporate growth. Out of the six material issues relating to “Realizing a Carbon Neutral Society and Striving to Enrich Society Both Materially and Spiritually”, this project’s activities particularly support “Contributing to Decarbonized Societies” and “Promoting Stable, Sustainable Societies and Lifestyles.”Inquiry RecipientMitsubishi CorporationTelephone:+81-3-3210-2171 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and SHANGHAI, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, “Henlius”) announced today the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) in Japan.Serplulimab, a novel anti-PD-1 monoclonal antibody developed by Henlius, is reported to possess a unique binding mode that differs from existing anti-PD-1 antibodies. 1 In China, it has been approved for indications such as squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsNSCLC), and esophageal squamous cell carcinoma (ESCC). In the EU, it has been approved for ES-SCLC. It is the world's first anti-PD-1 antibody to be used as a first-line treatment for ES-SCLC.In Japan, Henlius is currently conducting a Phase II bridging clinical trial for ES-SCLC, and plans to submit an application for fiscal year 2026 based on the results of this trial as well as the Phase III clinical trial data that supported approvals for this indication in China and Europe. Furthermore, a Phase III multi-national clinical trial for non-high-frequency microsatellite instability (non-MSI-High) metastatic colorectal cancer is underway, with development for new indications also planned.In Japan, it is estimated that there are approximately 13,000 patients diagnosed with ES-SCLC and about 28,000 patients diagnosed with non-MSI-High metastatic colorectal cancer, both of which are considered to have high unmet medical needs. 2,3,4,5Under the terms of this agreement, Eisai will obtain exclusive rights to commercialize serplulimab in Japan. In addition to ES-SCLC and non-MSI-High metastatic colorectal cancer, Henlius plans to also conduct a clinical trial for perioperative gastric cancer in Japan, and will assume the responsibilities of the Marketing Authorization Holder.Eisai will pay Henlius a contractual upfront payment of USD 75 million (approximately JPY 11.6 billion*), in addition to regulatory milestone payments of up to USD 80.01 million (approximately JPY 12.4 billion), and sales milestone payments of up to USD 233.3 million (approximately JPY 36.2 billion). Furthermore, Eisai will pay double-digit royalties based on sales of the product. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“We are pleased to collaborate with Eisai in Japan to advance the development of serplulimab in this important market,” said Dr. Jason Zhu, CEO of Henlius. “Serplulimab has demonstrated its potential across multiple tumor types through global clinical development and regulatory approvals, and Japan represents a critical step in its international journey. By combining Henlius’ innovation capabilities with Eisai’s deep local expertise, we aim to support the efficient development of serplulimab and address unmet medical needs for patients in Japan.”“Serplulimab is an anti-PD-1 monoclonal antibody that has been developed with high priority for indications with significant unmet medical needs, including ES-SCLC, and has already obtained approval for multiple indications in China and the EU. We anticipate that it will also become a promising treatment option in Japan for ES-SCLC and non-MSI-high metastatic colorectal cancer, for which development is underway, as well as for other intractable cancers,” said Toshihiko Yusa, Executive Officer and Head of Japan Business at Eisai. “Eisai will make every effort, in cooperation with Henlius, to deliver serplulimab to patients as soon as possible.”* Converted at an exchange rate of USD 1 = JPY 155MEDIA CONTACTSEisai Co., Ltd. Public Relations DepartmentTEL: +81 (0)3-3817-5120Shanghai Henlius Biotech Inc.Janice Hanjiayi_han@henlius.comBella Zhouwenting_zhou@henlius.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Shanghai Henlius Biotech Inc.Venus Hu junyan_Hu@henlius.com About SerplulimabSerplulimab (generic name, marketed as HANSIZHUANG in China and Hetronifly® in the EU) is an anti-PD-1 monoclonal antibody first developed by Shanghai Henlius Biotech, Inc. (“Henlius”), and launched in China in 2022. It has been approved by the National Medical Products Administration of China for indications including squamous non-small cell lung cancer, extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer, and is the world's first anti-PD-1 antibody to be used as a first-line treatment for ESSCLC. It has been approved for the treatment of ES-SCLC in over 40 markets, including the EU, Southeast Asia (Indonesia, Cambodia, Thailand, Singapore, Malaysia), and South America (Peru). Henlius is actively promoting the broader use of serplulimab both as a standalone product and in combination with other innovative therapies, including those developed in-house and externally. Furthermore, the company is conducting numerous clinical trials worldwide on therapies for conditions where existing anti-PD-1 antibodies have not yet been used, focusing on indications such as lung cancer and gastrointestinal tumors.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Shanghai Henlius Biotech, Inc.Shanghai Henlius Biotech, Inc. (2696.HK) is a global, innovation-driven biopharmaceutical company committed to delivering high-quality, affordable biologic therapies to patients worldwide. The Company focuses on major disease areas including oncology, autoimmune diseases, and ophthalmic diseases. Founded in 2010, Henlius has established an integrated, end-to-end biopharmaceutical platform encompassing global R&D, clinical operations, regulatory affairs, manufacturing, and commercialisation. The Company employs nearly 4,000 people globally and operates across multiple regions, including China, the United States, and Japan. Leveraging the stable cash flow generated from its biosimilar portfolio to support innovation, Henlius is steadily advancing into its “Globalisation 2.0” phase, building a scalable and sustainable global growth model. As of early 2026, Henlius has achieved regulatory approvals for 10 products across 60 countries and regions worldwide, including seven approvals in China. The Company has also reached multiple milestones in major biopharmaceutical markets, with four products approved by the U.S. Food and Drug Administration (FDA) and four products authorized by the European Medicines Agency (EMA), reflecting its globally aligned R&D capabilities, quality systems, and manufacturing standards.Driven by innovation, Henlius has built a diversified, platform-based technology ecosystem through coordinated R&D efforts across Shanghai, the United States, and other regions. Its innovation platforms span immune checkpoint inhibitors, immune cell engager technologies (including multispecific T cell engagers), antibody-drug conjugates (ADCs), and AI-enabled early discovery platforms. The Company currently has more than 50 early-stage innovative assets, approximately 70% of which are expected to be best-in-class, with over 30 clinical trials ongoing globally. Henlius’ core product, serplulimab (trade name: Hetronifly® in Europe), is the world’s first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and has been approved in more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity of 84,000L and GMP certifications from regulatory authorities in China, Europe, and the United States, Henlius has established a stable global supply system serving six continents. Guided by a patient-centred mission, Henlius remains focused on addressing unmet medical needs and translating scientific innovation into meaningful clinical value and patient access, contributing sustainably to the global biopharmaceutical ecosystem.To learn more about Henlius, visit https://www.henlius.com/en/index.html and connect with us on LinkedIn at https://www.linkedin.com/company/henlius/.References1. Issafras H, Fan S, Tseng C-L, Cheng Y, Lin P, Xiao L, et al. (2021) Structural basis of HLX10 PD1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS ONE 16(12): e0257972. https://doi.org/10.1371/journal.pone.02579722. National Cancer Center Japan, Cancer Information Service, Cancer Statistics (Japanese only) https://ganjoho.jp/reg_stat/statistics/stat/cancer/index.html Last accessed: January 2026.3. Sabari, J., Lok, B., Laird, J. et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14, 549–561 (2017).4. Fujiyoshi K, Yamamoto G, Takenoya T et al. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor. Anticancer Res. 2017;37(1):239- 247.5. Cancer Statistics in Japan-2025 https://www.fpcr.or.jp/pdf/pamphlet/cancer_statistics_2025.pdf (P30) Last accessed: January 2026. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kawasaki and Tokyo, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Japan Limited and JMDC Inc. today announced the commencement of a collaboration aimed at advancing medical care and contributing to the establishment of a sustainable healthcare system in Japan.This collaboration, which began on January 5, leverages JMDC's expertise in utilizing anonymized medical data and Fujitsu Japan's customer base. Fujitsu Japan holds the top share in the Japanese electronic health record (EHR) market for medical institutions. This synergy will accelerate the utilization of medical data by medical institutions and organizations that are part of the healthcare system, while also supporting data-driven management decision-making.This collaboration will see the two companies combine Fujitsu Japan's knowledge in the medical field and advanced technologies including AI, with JMDC's prediction models based on insurance user data and its expertise cultivated through Pep Up, one of Japan's largest personal health record services used by 7.7 million people. This will expand the scope of data utilization from DPC data [1] to comprehensive EHR data. This initiative will further promote the utilization of medical data, contributing to improved management for medical institutions and advanced research for pharmaceutical companies, government agencies, and academia.Going forward, Fujitsu Japan will contribute to the realization of digital hospitals that promote DX in medical institutions, while JMDC will advance initiatives that contribute to "building a sustainable healthcare system through addressing social issues with the power of data and ICT" and "accelerating the societal integration of data."Overview of the collaborationFujitsu Japan will provide Dashboard 360, a solution that enables visualization and analysis of management and clinical data, free of charge [2] to medical institutions that agree to provide anonymized DPC data [3]. Dashboard 360 is offered as part of Fujitsu Limited's Uvance business model, which addresses societal challenges, specifically within the Smart Hospital offering that maximizes hospital operational efficiency and effectiveness. It is a component of the Healthcare Management Platform, a suite of services designed to optimize patient flow [4] in acute care hospitals and support the resolution of management challenges.Dashboard 360 seamlessly integrates with EHRs, allowing for factor analysis of issues such as declining bed occupancy rates and waiting times for hospitalization or surgery, based on information including inpatient care and outpatient conditions leading to hospitalization. It also features a benchmarking function, utilizing data provided by JMDC and DPC data from medical institutions, to support timely decision-making in hospital management.JMDC will collaborate with Fujitsu Japan to anonymize DPC data in a secure environment and provide it to pharmaceutical companies, government agencies, and universities for research purposes. Additionally, by combining this with JMDC's accumulated insurance user data, covering approximately 20 million individuals, the collaboration will visualize the entire patient journey from pre-onset abnormal test results to inpatient treatment and post-discharge prognosis. This will enable early detection of diseases through screening of potential patients, prevention of severe cases by identifying risk factors, and precise evaluation of long-term treatment effects and drug safety in real-world settings, thereby contributing to the improvement of medical quality and efficiency.Figure: Collaboration overviewBackgroundIn Japan, the aging population and increasing medical expenses are pressing concerns. Challenges such as a shortage of healthcare professionals and financial difficulties for medical institutions persist. By leveraging medical data, it is expected that these challenges can be addressed through improved diagnostic accuracy, enhanced operational efficiency, development of new treatment methods, and strengthened regional healthcare collaboration.[1] DPC data:Data used to calculate medical costs based on the patient's diagnosis and treatment content during hospitalization. It includes patient information, diagnoses, surgical procedures, medications used, and is expected to be utilized for analyzing medical quality and hospital management, as well as for formulating healthcare policies.[2] Agreement to provide anonymized DPC data:Fujitsu Japan is entrusted by medical institutions with the creation of anonymized information such as DPC data, and the medical institutions grant Fujitsu Japan permission for secondary use of the created anonymized information.[3] Free of charge:No initial setup or usage fees. A separate license fee for the BI tool included in the service is required.[4] Patient flow:The management of the entire patient process from hospital visit to discharge.About FujitsuFujitsu's purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout JMDCEstablished in 2002 as a pioneer in the medical big data industry, JMDC possesses proprietary anonymization processing technology and data analysis/aggregation technology. Based on the analysis of over 1.573 billion medical claims data and over 76 million health checkup data (as of March 2025), JMDC provide information services, including support for health promotion programs for payers, drug safety evaluation, and healthcare economics analysis. JMDC is committed to realizing a healthy society through medical data and analytical capabilities, providing a single index for health (Health Age) and web services for health promotion (Pep Up), among others. Find out more: https://www.jmdc.co.jp/en/Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesJMDC Inc.JMDC Inc. IR OfficeEmail: jmdc-pr@jmdc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Tokyo and Kawasaki, Japan, Feb 6, 2026 - (JCN Newswire via SeaPRwire.com) - Genesys® Cloud Services, Inc. (Headquarters: Minato-ku, Tokyo; President: Paul Ito Ricci, hereinafter Genesys), a global cloud leader in AI-Powered Experience Orchestration, and Fujitsu Limited (Headquarters: Kawasaki City, Kanagawa Prefecture; President and CEO: Takahito Tokita; hereinafter Fujitsu) which led the implementation of Genesys Cloud, announced the successful transformation of AEON Financial Service Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo; President and CEO: Tomoharu Fukayama; hereinafter AEON Financial Service) contact center operations and the completion of its effectiveness evaluation.As part of this contact center transformation initiative, AEON Financial Service deployed Genesys Cloud™, a unified experience orchestration platform. Because of the composability of the Genesys Cloud platform, Fujitsu implemented customizations to meet its unique business requirements, including reporting management and system integrations, and will continue to support maintenance and operations. With over 2,500 seats, this deployment is among the largest of its kind in Japan’s financial sector.AEON Financial Service plans to introduce an “AI Concierge (Voice Bot)” utilizing speech recognition technology. This will allow customers to be guided to the appropriate menu through natural spoken dialogue, eliminating the need for phone keypad input. Furthermore, AEON Financial Service is considering expanding the solution to other contact centers across the AEON Group. Genesys and Fujitsu will continue to support the advancement of contact center systems across the entire AEON Group.Paul Ito Ricci, President of Genesys Japan, commented:"AEON Financial Service is demonstrating how modern experience orchestration can transform customer engagement at scale in a short period.By moving its contact center platform to the cloud, the company has been able to internalize system development and significantly accelerate the speed at which it can deliver more convenient services to address customers’ needs. . We are committed to supporting AEON Financial Service through Genesys Cloud as they utilize AI to deliver innovative, personalized and empathic customer experiences and seamless support for each individual at scale."Masaru Yagi, Executive Vice President, Fujitsu Limited, commented:"We are pleased to announce the successful introduction of Genesys Cloud to enhance the contact center operations for AEON Financial Service. This initiative addresses the crucial and growing need for contact center transformation in recent years. We are confident that this project meaningfully contributes to establishing an operator-first environment where high-quality customer experience can be delivered without added burden. Fujitsu will continue to support the implementation and operation of Genesys Cloud as a solution vendor, leveraging AI and other technologies to support AEON Financial Group and many other companies."BackgroundAEON Financial Service call center is responsible for comprehensive support across a wide array of financial services, including banking, insurance, and loans, in addition to payment services such as AEON Pay, AEON Card, and WAON. A significant challenge for the company was the increase in customer waiting times due to the growing variety of inquiry types and the increasing specialization and segmentation of internal guidance points. Moreover, the conventional on-premises call center system required modernization to effectively support future service expansion.Improvements driven by the contact center operations overhaulFollowing the deployment of Genesys Cloud and the overhaul of its contact center operations, AEON Financial Service has realized the following benefits within the first six months:1. Higher self-service completion ratesBy expanding self-service options within the IVR (Interactive Voice Response) system, the self-completion rate for the menu option that allows customers to report payments after a failed withdrawal improved by 21 percentage points compared to the previous system, helping reduce customer wait times.2. Automated SMS supportBy implementing a mechanism that automatically sends an SMS in response to IVR inquiries, simple questions can now be resolved through self-service. This allows operators to concentrate on more complex tasks.3. Rapid feature enhancements and flexible operationsThe use of a cloud service with the requirement of a low-code functionality enables the speedy deployment of new services and quick changes to the IVR structure. Furthermore, future efforts to bring development in-house will allow for even faster response times.About GenesysGenesys® empowers more than 8,000 organizations worldwide to create the best customer and employee experiences. With agentic AI at its core, Genesys Cloud™ is the AI-Powered Experience Orchestration platform that connects people, systems, data and AI across the enterprise. As a result, organizations can drive customer loyalty, growth and retention while increasing operational efficiency and teamwork across human and AI workforces. www.genesys.com/ja-jpAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesGenesys Cloud Services, Inc. Genesys PR Office (Initial Inc.)Contacts: Hirabayashi, Nagaoka, AkiyamaTel: +81-3-5572-7334 Email: genesys_pr@vectorinc.co.jp Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Feb 5, 2026 - (JCN Newswire via SeaPRwire.com) - TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd. (Head Office: Chuo-ku, Tokyo; Representative Director & CEO: Koichiro Tanaka), a company engaged in the industrial precious metals business of TANAKA, announced today that it has established a total solution system capable of supporting all processes in the contract manufacturing business for various test kits including in vitro diagnostics.Until now, TANAKA has been responsible primarily for processes from developing and manufacturing test kits to bulk production of extraction buffer. At this time, TANAKA established dedicated production lines for the dispensing and packaging of extraction buffer, creating a system that enables it to complete all processes in-house from development to manufacture of final products. This enables TANAKA to reduce costs and the time for external outsourcing and transportation, making it possible to deliver high-quality products in shorter times.In addition, TANAKA will seek to expand production capacity and shorten lead times even further by introducing additional state-of-the-art automatic assembly lines and extract dispensing equipment with a target of March 2026.TANAKA's Total Solution SystemFlexible responses achieved through reinforced integrated production systemBy establishing this total solution system, TANAKA will be able to provide comprehensive contract services covering all processes from test kit development and manufacturing to bulk production, dispensing, and packaging of extraction buffer. This will enable TANAKA to continuously support customers from the development stage through mass production while also accommodating request for individual processes such as extraction buffer dispensing only.By bringing production processes entirely in-house, TANAKA will further reinforce stable supply and quality control.A track record in the development of diagnostic test kits across a wide range of disease areas and examples of deploymentTANAKA offers in vitro diagnostics for a wide range of infectious diseases including respiratory tract infections, such as influenza and COVID-19, as well as dengue and ZIKA viruses. These test kits are compatible with various sample types such as saliva, blood, and urine, and support rapid and accurate testing in clinical settings.Respiratory Tract InfectionsMosquito-Born Infectious DiseasesObstetrics・ Influenza virus・ Adenovirus・ RS virus・ Human meta-virus・ COVID-19・Group A beta hemolytic Streptococcus (Streptococcus pyogenes)・ Dengue virus・ Zika virus・ Chikungunya virus・ Pregnancy testingExamples of Disease Areas That TANAKA Deploys Tests ForTechnical foundations and future outlookTANAKA started research and development of in vitro diagnostics around 2006 and has accumulated technologies centered on nano-colloidal gold (Au). It possesses a diverse range of technologies that support the enhancement of reagent performance using immunochromatographic assay, including protein immobilization technology, non-specific absorption expression technology, and antigen-antibody reaction enhancement technology, TANAKA provides contract manufacturing of high-quality test kits that leverage these technologies in accordance with the ISO 13485 system.Going forward, TANAKA will leverage this total solution system to develop new diagnostics in collaboration with partner companies, while contributing to solutions to social issues and advancement of the field of medicine.About TANAKASince its foundation in 1885, TANAKA has built a portfolio of products to support a diversified range of business uses focused on precious metals. TANAKA is a leader in Japan regarding the volume of precious metals it handles. Over many years, TANAKA has manufactured and sold precious metal products for industry and provided precious metals in such forms as jewelry and assets. As precious metals specialists, all Group companies in Japan and worldwide collaborate on manufacturing, sales, and technology development to offer a full range of products and services. With 5,591 employees, the group’s consolidated net sales for the fiscal year ended December 2024 were 846.9 billion yen.TANAKA Industrial Precious Metal Materials Portalhttps://tanaka-preciousmetals.comProduct inquiriesTANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-on-industrial-products/Press inquiriesTANAKA PRECIOUS METAL GROUP Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/Press release: https://www.acnnewswire.com/docs/files/20260205_EN.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE. NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com